RBC Capital Stays on the Sidelines with Bluebird Bio (BLUE) Despite Abecma's Approval
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated a Sector Perform rating and $37.00 price target on bluebird bio (NASDAQ: BLUE) noting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
